Aims: The abundance of beta3-adrenergic receptors (β3-ARs) is upregulated in diseased human myocardium. We previously showed that cardiac-specific expression of β3-AR inhibits the hypertrophic response to neurohormonal stimulation. Here, we further analyzed signalling pathways involved in the anti-hypertrophic effect of β3-AR.
INTRODUCTION
Haemodynamic overload, ischemic or oxidative stress promote adverse cardiac remodelling, a leading cause of worsening heart failure 1 . Most of these pathophysiologic conditions are associated with adrenergic stimulation, resulting in adrenoceptor (AR) activation on different cell types within the myocardium. Among these, β1-AR's are classically considered to mediate short-term positive effects on all aspects of myocardial contractility; however, long-term stimulation produces adverse effects on myocardial remodelling, in part through activation of calcium-dependent pro-hypertrophic effects, ultimately associated with cardiomyocyte loss 2 . Such "maladaptive" remodelling is usually accompanied with left ventricular (LV) geometry disruption and interstitial fibrosis leading to progressive diastolic and systolic heart failure. Conversely, β3-AR mediates effects on cardiac myocytes that are antipathetic to β1-AR, i.e. protection from hypertrophic 3 or fibrotic 4 remodelling. Deciphering the underlying signalling pathways should yield new therapeutic strategies to favourably modulate remodelling.
AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase composed of one catalytic (AMPKα) and two regulatory subunits (AMPKβ and AMPKγ) present under several isoforms (two for α and β and three for γ) 5 . AMPK is an important cellular sensor of energy level.
Its activation derives from an increase in the intracellular AMP-to-ATP ratio that typically occurs during metabolic stresses, such as myocardial ischemia 6 . AMP stimulates AMPK allosterically via its binding to the AMPK γ-subunit and protects AMPK from de-phosphorylation on Thr172, a residue located in the activation loop of the AMPKcatalytic subunit. Once activated, AMPK participates in the maintenance of energy homeostasis by switching off anabolic pathways that consume ATP and switching on alternative catabolic pathways that generate ATP 7 . It is currently recognized that AMPK effects extend beyond its metabolic role 7 . In agreement, it has been shown that AMPK activation prevents cardiac hypertrophy development 7 . Accordingly, AMPK deletion leads to enhanced hypertrophy 8 . At the molecular level, AMPK is known to inhibit the mechanistic target of rapamycin (mTOR) pathway via a complex mechanism 7 . The mTOR pathway promotes protein synthesis and inhibits autophagy.
Consequently, AMPK activation leads to a net balance in favour of protein degradation.
Autophagy is a conserved process from yeast to mammals for the bulk degradation and recycling of long-lived proteins and organelles 9 . Intracellular components are surrounded by double membrane-bound autophagic vesicles which then fuse with lysosomes to form autolysosomes for degradation.
Controlled by autophagy-related proteins (Atgs) such as Atg5 and 7, beclin 1 and microtubule-associated protein 1 light chain 3 (LC3), autophagy plays an essential role in maintaining cellular homeostasis and was initially believed to be a non-selective process. In eukaryotic cells, autophagy occurs constitutively at low levels to facilitate homeostatic functions such as protein and organelle turnover 10 . It is rapidly upregulated when cells need to generate intracellular nutrients and energy or to remove damaging components resulting from oxidative stress or protein aggregates accumulation. Increasing evidence demonstrates that autophagy plays an essential role in cardiac remodelling to maintain cardiac function and cellular homeostasis in the heart. In certain circumstances, when excessive, the pro-survival functions of autophagy may paradoxically become deleterious 10, 11 .
In this study, we dissected the signalling pathway involved in the anti-hypertrophic effect of the human β3-AR expressed in rodent cardiac myocytes, as previously used by us 3, 4 . We identified β3-AR coupling to AMPK and downstream autophagy as key components for this protection.
METHODS

Animals
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1985). All experimental protocols were approved by the local Ethics Committee.
Male mice harbouring an α-MHC-driven human β3-AR transgene (β3-TG), generated as described previously 12 , were used between 12-16 weeks. Ascending aorta constriction was performed as described 4 . Briefly, after anesthetizing, a constrictive band was placed and tightened around the aorta constricted by a cannula with a width of 27G. The ligature was not tightened in sham-operated mice.
Doppler measurements of trans-stenotic gradients were systematically performed at day 1, week 3 and 9 post-surgery. Only mice with a velocity higher than 2.5m/s were kept into the experiment. Mice were also submitted to the protease inhibitor leupeptin treatment to inhibit autophagic degradation (Leup, 40mg/kg, IP, 1h).
In vitro cardiac myocytes preparations
Adult mouse ventricular myocytes (AMVM) were isolated from the hearts of 8 week-old β3-TG mice. Mice were killed by an intraperitoneal injection of sodium pentobarbital overdose (300 mg/kg) with heparin (8,000 units/kg), and the heart was rapidly excised. The ascending aorta was cannulated with a needle, and the heart was retrogradely perfused in a Langendorff perfusion system at 37°C for 5 min with perfusion buffer. This was followed by 8 min of perfusion with digestion buffer (4mg/mL trypsin, 5mg/mL liberase (Roche) and 0.3mM CaCl2). The ventricles were removed, chopped into small pieces in stop buffer (BSA 50mg/mL, 0.12mM CaCl2) and gently agitated for 3 min. The supernatant containing isolated myocytes was centrifuged (1000 rpm for 1 min), and the myocytes were resuspended in stop buffer, and subjected to a step-wise recalcification protocol (5 x 4 min stepwise increase in CaCl2 concentration from 62μM to 112μM to 212μM to 500μM to 1mM). The myocytes were plated on laminincoated Labtek culture slides. After 1h, stop buffer was replaced by plating medium (MEM with GBS 5%, BDM 10mM, penicillin 100 U/mL and L-Glutamine 2mM).
Ventricular myocytes from 1-2 days old neonatal rats (NRVM) were isolated by collagenase/pancreatin digestion as previously described 3 . Approximately 20h post-isolation, myocytes were transferred to serum-free media and infected with a recombinant adenovirus encoding a polycistronic construct encoding the human β3-AR cDNA (form C) and GFP at a multiplicity of infection of 1.5 plaque forming units per cell; an adenovirus encoding GFP only was used as control. 24h after infection, myocytes were treated with either phenylephrine (PE, 20µM) to induce hypertrophy and/or the protease inhibitor leupeptin to inhibit autophagic degradation (Leup, 150µM) in serum-free conditions.
AMPK knockdown by small interfering RNA transfection
NRVMs at a confluence of 50% were transfected with either control non-targeting siRNA or pooled siRNA targeting both AMPKα1 and AMPKα2 catalytic isoforms (AMPKα1/α2 siRNA) (from GE Healthcare 50nM) using lipofectamine RNAimax transfection reagent (Invitrogen) according to the manufacturer's protocol. Phenylephrine treatment was started 66h post-siRNA transfection.
Subcellular fractionation
Left ventricular extracts were prepared in 1 mL of 0.5M Na2CO3 (pH 11) and added to 1 mL of 80% sucrose (in 0.15M NaCl; 25mM MES, pH 6.5; final sucrose concentration, 40%). A 2-step gradient was loaded on the top of the sample (4 mL of 35% sucrose overlaid with 4 mL of 5% sucrose). After ultracentrifugation at 38000 rpm (18h, 4°C), fractions were collected from top to bottom, precipitated with trichloroacetic acid (7.2%), washed, and resuspended in Laemmli for discontinuous (8% to 12% SDSpolyacrylamide) electrophoresis and immunoblotting with antibodies (Supplemental Table 1 ).
Western blotting
Denatured proteins were separated by SDS-PAGE, transferred on nitrocellulose membrane, then blocked 1h in 5% non-fat dry milk in TBS-Tween and incubated overnight in 1% milk Tween-TBS with primary antibodies. Following washing (3 x 10 min in Tween-TBS) membranes were incubated with relevant secondary antibodies in 1% milk Tween-TBS. After a final washing step (3 x 10 min Tween-TBS), membranes were revealed by chemiluminescence. Further details on primary and secondary antibodies are provided in Supplemental Table 1 .
Radiolabeled aminoacids incorporation:
NRVM were plated at 1,000,000 per plate in 6-wells plates. After infection, myocytes were treated at the same time with PE (20µM) and [ 14 C]l-phenylalanine (5µCi/mL) in serum-free conditions for 24h. Cells were then lysed in 50mM HEPES, 50mM KF, 1mM Kpi, 5mM EDTA, 5mM EGTA, 15mM βmercapto-ethanol, 5% triton and incubated with 10% trichloroacetic acid for 20 min at 4°C to precipitate proteins. Precipitated material was neutralized with 100mM NaOH. The samples were precipitated a second time with 10% trichloroacetic for 20 min at 4°C. After re-suspension of protein pellets in formic acid, incorporated radioactivity was measured by liquid scintillation counting.
Histology and immunostaining
All morphometric and histologic measurements were obtained from hearts arrested in diastole (intracardiac KCl), washed and fixed. Transversal cryo-sections were defrosted slowly in acetone, before washing (PBS; 3 x 5 min). Sections were then incubated with Wheat germ agglutinin (WGA, 1/150; 2h, in the dark). After additional washing, sections were mounted with Vectashield and observed with Axioimager Z1 Apotome system with MRm Rev3 AxioVision-Deconvolution 3D camera. Data from multiple sections per heart were analyzed using AxioVision software 4.8.2.0 (Carl Zeiss MicroImaging GmbH, Germany).
Immunofluorescence and Proximity Ligation Assay
NRVM were fixed with 4% paraformaldehyde in PBS for 20 min. After washes (PBS, 3 x 5 min), cells were permeabilized with 0.1% triton X-100 in PBS for 10 min. After 3 washes, cells were incubated with 5% BSA in PBS for 30 min and then incubated with anti-alpha-actinin or LC3 primary antibody (Supplemental Table 1 ) overnight at 4°C. After 3 washes, cells were incubated with secondary antibodies diluted at 1/300 for 1h, then with Dapi 1/50000 in PBS for 5 min and mounted.
A PLA kit II (Eurogentec, Seraing, BE) was used according to the manufacturer's instructions with slight modifications. Briefly, cardiomyocytes were fixed and transiently permeabilized (with 4% paraformaldehyde in PBS; 10 min), washed (PBS; 2 x 2 min), quenched (50mM NH4Cl; 2 x 5 min), washed, and blocked (blocking buffer; 30 min, 37°C) before being incubated overnight (4°C) with primary antibodies (Supplemental Table 1 ). The following day, cardiomyocytes were washed (Buffer A; 2 
Statistical analysis
Results are expressed as mean ± SEM calculated from the measurements obtained from each group of cells and mice. When normal distribution (Kolmogorov-Smirnov test) was confirmed, raw data were analyzed using 2-way ANOVA followed by Bonferroni post-hoc test for multi-group comparisons.
In absence of normal distribution, data were compared using nonparametric tests (Kruskall-Wallis followed by Dunn correction for multiple comparisons or Mann-Whitney). Statistical significance was accepted at the level of P<0.05
RESULTS
β3-AR and AMPK are co-localized in caveolae
We used a transgenic mouse line with cardiac myocyte-specific, moderate level expression of the human β3-AR (β3-TG) to examine the subcellular distribution of the β3-AR and AMPK. Cardiac extracts were resolved by isopycnic ultracentrifugation. As previously shown, the β3-AR protein was mainly distributed in light fractions, together with a majority of caveolin-3 (Cav-3), the main caveolar coat protein expressed in muscle cells 3 . Moreover, in the same extracts, a part of AMPK (using antibody recognizing both AMPKα1/2 catalytic subunits) co-segregated with Cav-3 signals ( Figure 1A ). To verify that this corresponds to the location in intact cells, we used proximity ligation assay to examine the colocalization of AMPK and Cav-3 in AMVM; as illustrated in Figure 1B , positive fluorescence signals indicated co-localisation of the 2 proteins in adult cardiomyocytes.
Effect of neurohormonal stimuli on AMPK signalling pathway in neonatal cardiac myocytes
To examine how expression of the β3-AR could attenuate hypertrophy in response to a neurohormonal stimulus, we used an in vitro model of homotypic cultures of cardiac myocytes (NRVM) with adenoviral expression of the human β3-AR (AdV-β3-AR) or GFP used as control (AdV-GFP). AdV-β3-AR-infected NRVM expressed human β3-AR transcripts in proportion to the titer of recombinant viruses, as measured by RT-qPCR ( Figure 2A ). Immunofluorescence staining confirmed the expression of the human β3-AR protein at the membrane of infected NRVMs ( Figure 2B ). We also used proximity ligation assay to examine the co-localization of AMPK and β3-AR in NRVM; as illustrated in Figure 2C , positive fluorescence signals indicated co-localisation of the 2 proteins both in Adv-GFP and in AdV-β3-AR-infected neonatal cardiac myocytes, both in absence and after stimulation with phenylephrine. No PLA signal was observed in negative controls (i.e. in the absence of either primary antibody). Control, GFP-infected myocytes developed hypertrophy in response to phenylephrine (PE) 3 . This was associated with a decrease in AMPK signalling pathway, identified by a decrease in Thr172 phosphorylated-AMPK ( Figure 2BD ) and a decrease in phosphorylation of its substrate acetyl-CoA carboxylase (ACC) on Ser79
( Figure 2E ). The inhibition of AMPK pathway correlated with the activation of mTOR pathway, assessed from the phosphorylation state of its indirect downstream target, the ribosomal S6 protein (S6) on Ser235/236 ( Figure F ). This was associated with an increase in radiolabelled amino acids integration into proteins ( Figure 2G ). In contrast, AdV-β3-AR infected myocytes retained basal level of AMPK, ACC and S6 phosphorylation and unchanged protein synthesis rate despite PE stimulation ( Figure 2D-G) .
Effect of haemodynamic overload on AMPK signalling pathway in mice
Adult β3-TG mice were subjected to transaortic constriction (TAC) and their phenotype analysed at 9 weeks post-TAC. Morphometric data are illustrated in Figure 3A . All parameters were identical between genotypes in sham-operated mice. All mice included in the TAC study (β3-TG and WT) developed a trans-stenotic gradient with maximum velocity (by Doppler echo) of at least 2.5 m/s, and gradients were comparable between genotypes. WT mice developed myocardial hypertrophy, as evidenced by an increase in left ventricular weight (LVW) normalized to tibial length (TL) ( Figure 3A) and increased myocyte transverse area measured histologically ( Figure 3B ). However, increases in both parameters were significantly milder in β3-TG mice.
At the molecular level, 9 weeks of TAC resulted in a significant decrease in AMPK signalling, as identified by a decrease in AMPK phosphorylation on Thr172 ( Figure 3C ), a decrease in ACC phosphorylation on Ser79 ( Figure 3D ) and an increase in S6 phosphorylation on Thr389 ( Figure 3E ) in WT mice. However, basal levels of phospho-Thr172-AMPK ( Figure 3C ), phospho-Ser79-ACC ( Figure   3D ) and phospho-Thr389-S6 ( Figure 3E ) appeared unchanged, albeit with some variability, from shamoperated controls in β3-TG mice. 
Role of AMPK in the anti-hypertrophic effect of β3-AR
Effect of neurohormonal stimuli on autophagy signalling pathway in cardiac myocytes
Control AdV-GFP infected myocytes developed hypertrophy in response to PE together with a decrease in autophagy identified by a decrease in LC3 II/I ratio ( Figure 5A) , an increase in p62 expression ( Figure 5B ) and a 24.5% decrease of autophagic cells (by LC3 immunostaining quantification) ( Figure   5C ). By contrast, AdV-β3-AR infected myocytes maintained their basal level of autophagy (monitored with the same 3 criteria) despite PE stimulation. Of note, a similar decrease in LC3 II/I ratio was observed after TAC in myocardial extracts from WT mice; however, basal levels were again maintained in β3-TG mice after TAC ( Figure 5D ).
We then analysed autophagic flux by inhibiting autophagic degradation with the protease inhibitor leupeptin ( Figure 6 ). As expected, leupeptin treatment increased the level of LC3 II/I ratio and percentage of LC3-marked cells in AdV-GFP infected myocytes, unravelling a basal autophagic flux ( Figure 6A and C). Leupeptin also reversed the decrease of these indexes induced by PE treatment (Figure 6A and C).
However, leupeptin had no effect in AdV-hβ3 infected myocytes, suggesting that autophagy is already maximal in these cells, with or without PE ( Figure 6B ). Interestingly, these effects of leupeptin were reproduced in hearts of WT and β3-TG mice ( Figure 6D ) after i.p. injection. Similar effects were reproduced with chloroquine that inhibits the autophagososme-lysosome fusion and degradation (not shown).
DISCUSSION
The main findings of this study are as following; i. the β3-AR co-localizes with (part of) AMPK in caveolae-enriched membrane fractions of AMVM; ii. β3-AR expression restores basal level of AMPK signaling and autophagy in response to neurohormonal (PE) and haemodynamic (TAC) stress; iii. AMPK is, at least partially, involved in the anti-hypertrophic effect of β3-AR.
The β3-AR was first cloned from a human adipocyte cDNA library and is expressed mainly in brown/beige adipocytes, where it mediates non-shivering thermogenesis 13 . It was later found to be expressed in cardiac myocytes from several species, including human ventricular cardiac biopsies in which, contrary to β1-2ARs, β3-AR stimulation decreases contractile tone in vitro 14 . As β3-AR expression increases in cardiomyopathic hearts 15 , this led to the hypothesis that β3-AR may confer protection from the deleterious overstimulation of β1-2AR as observed in the course of heart failure progression 16, 17 . In this study, we used a heterozygous transgenic mouse with cardiac-specific, moderate expression of the human β3-AR that replicated the expression level of the receptor and the functional response to β3-AR agonists observed in human biopsies 4, 12 . Contrary to β1-2 AR transgenics, these β3-AR transgenic mice are protected from neurohormone and TAC-induced hypertrophic remodelling 3 . The present study analysed the precise mechanisms underlying this protection.
We previously reported that the recombinant β3-AR co-localized with caveolin-3 in lipid rafts/caveolae 3 , together with the endothelial nitric oxide synthase (eNOS) 17 . Here, we show that AMPK is also partially expressed in caveolae as previously observed in rat cardiac myocytes 18 .
Since adult cardiomyocytes have little capacity for cellular proliferation, their only means of growth is hypertrophy. Cardiac hypertrophy is considered to be an initially adaptive response, counteracting increased wall tension and helping to maintain cardiac output. Cardiac mass is determined by the balance between protein synthesis and degradation, known to be tightly regulated during the development of cardiac hypertrophy 19 . Accordingly, we observed that hypertrophy induced a decrease in phosphorylation of AMPK on its Thr172 activation site, resulting in AMPK signaling pathway inhibition.
Modulation of AMPK activity during cardiac hypertrophy is controversial in the literature. Indeed, in one study, no modification in AMPK activity or phosphorylation was found during the first 8 weeks of TAC-induced hypertrophy 20 whereas another study reported an activation after 17 to 19 weeks post-surgery 21 .
Such late AMPK activation can be hypothesized as a negative feedback mechanism to reduce hypertrophy progression. In both in vitro and in vivo protocol settings used in our study, hypertrophic stimuli clearly induced AMPK inhibition. Hypertrophy-mediated AMPK downregulation was associated with a decrease in S6 phosphorylation and an increase in radiolabelled aminoacid incorporation into proteins. Expression of the human β3-AR clearly restored AMPK signaling pathway, and attenuated hypertrophy in PEstimulated NRVMs and hearts with TAC-induced hypertrophic remodelling. The implication of AMPK downstream β3-AR activation was clearly demonstrated in vitro with the use of specific siRNA against AMPK catalytic subunits, which partly restored the hypertrophic response in β3-AR overexpressing cells. This is in line with recent data showing that exercise training protects the heart against ischemia/reperfusion injury by activating eNOS via the stimulation of a β3-AR-AMPK signaling pathway 22 . Note that we previously demonstrated that the heterologously expressed β3-AR is constitutively active 3 , explaining its tonic effect in absence of stimulation with specific agonists.
Nevertheless, despite AMPK silencing, the β3-AR retained a diminished, but still present antihypertrophic effect, that could be explained by alternative coupling to pathways downstream endothelial (e-) and neuronal (n-) nitric oxide synthases (NOS), as previously reported by us 3 . mTOR integrates upstream signals from various stresses such as cellular energy levels and inhibits autophagy. Reciprocally, AMPK could activate autophagy by inhibiting mTOR and both AMPK and mTOR can themselves be phosphorylated by Unc-51-like autophagy activating kinase 1 (ULK1), providing an additional level of regulatory feedback to modulate autophagy 23 . Autophagy is an evolutionarily conserved mechanism that targets damaged proteins or organelles for degradation through lysosomes. Autophagy can be non selective or organelle-specific, such as mitochondria-specific autophagy and plays an essential role in maintaining cellular homeostasis in the heart at baseline and in response to stress. Indeed, reduced autophagy gradually accumulates harmful proteins and generates reactive oxygen species from damaged mitochondria in the hypertrophied hearts. In line with this, we observed that TAC-or PE-induced hypertrophy was accompanied with a decrease in autophagy both in vitro and in vivo and expression of the human β3-AR restores autophagy, consistent with its protective effect against hypertrophy and remodelling. We used leupeptin, an inhibitor of autophagolysosomal proteases, (as well as chloroquine, an inhibitor autophagosome-lysosome fusion and degradation) to monitor autophagic flux in these models. Leupeptin has already been reported to induce LC3II accumulation in adult rat cardiomyocytes 24 . As expected, we observed an accumulation of LC3II in NRVMs and hearts treated with these inhibitors. Interestingly, leupeptin (or chloroquine) did not further increase LC3II in β3-AR-expressing myocytes in vitro or in vivo, possibly because autophagy flux may already have been maximally stimulated.
These results are consistent with previous observations on autophagy in cardiac hypertrophy.
Indeed, autophagy was shown to be suppressed in TAC-induced hypertrophied hearts at 1 week postsurgery compared to sham-operated hearts 25 or diminished in response to supravalvular aortic constriction 26 or β-adrenergic stimulation 27 . Interestingly, autophagy has been shown to participate in the anti-hypertrophic action of AMPK 28 . Nevertheless, we cannot exclude that β3-AR may activate autophagy independently of AMPK at this point. More generally, autophagy is also decreased in the aging heart whereas cardiovascular diseases progressively increase with age 29 . Increasing evidence suggests that autophagy is involved in the regulation of lifespan and aging. Autophagy may be especially important in non-proliferating cells, such as differentiated cardiac myocytes, in which there is no dilution of accumulated toxic material with cell division.
Limitations and perspectives: Admittedly, our observations are based on models with heterologous expression of a recombinant human β3-AR in cardiac myocytes in vitro and in vivo, with the caveat that genetically reconstituted signalling may not faithfully replicate the coupling of the endogenous receptor in situ. However, we used a line of transgenic animals selected on the basis of levels of β3-AR expression that replicates the abundance observed in human myocardial biopsies, as demonstrated previously 4 . Given the ubiquitous expression and widespread role of AMPK, it would be of interest to verify similar coupling to β3-AR in other tissues. β3-AR transcripts 30 and proteins 31 have clearly been identified in human white and brown adipocytes, where they can be activated by selective β3-AR agonists, such as mirabegron 30 . Given the emerging importance of brown adipose tissue in regulating metabolism and cardiovascular function 32, 33 , and the role of AMPK in promoting mitochondrial biogenesis 34 , critical for brown fat lipolytic activity, we can speculate that the β3-AR coupling mechanism identified here could be exploited therapeutically to prevent or treat cardiovascular diseases associated with obesity and disordered metabolism. Such systemic effects are currently being studied in the European BETA3-LVH trial testing the re-purposing of mirabegron in patients with structural cardiac remodelling with or at risk of developing heart failure with preserved ejection fraction 35 . Further, β3-AR modulation of visceral adipose tissue may have remote effects on cardiac aging by regulating fibroblast senescence 36 , although this has not been directly demonstrated so far.
In conclusion, moderate expression of β3-AR in cardiac myocytes protects from myocardial remodelling by modulation of AMPK signaling pathway and autophagy. These observations may open new therapeutic perspectives with specific β3-AR agonists for the treatment of hypertrophic cardiomyopathies.
LEGENDS Figure 1. β3-adrenoceptor and AMPK subcellular localization in β3-transgenic mouse hearts
A. Subcellular fractionation of cardiac extracts of TG mice separated by ultracentifugation on sucrose gradients; each fraction (1 to 10 fractions of increasing densities) was analysed by immunoblotting for AMPK, hβ3-AR and myocyte-specific caveolin-3 (Cav Negative control in absence of primary antibody for AMPK for colocalization of hβ3-AR and AMPK in AdV-GFP (control) and AdV-β3-AR-infected NRVM by Proximity Ligation Assay. Scale bar is 50 µm.
